Invega Sustenna
Rx75 mg • IM Injection
Indications & Uses
Invega Sustenna is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Schizophrenia: Initiation Dosing: Day 1-234 mg and Day 8-156 mg Monthly Maintenance Dose: 39-234 mg Maximum Monthly Dose: 234 mg Schizoaffective disorder: Initiation Dosing: Day 1-234 mg and Day 8-156 mg Monthly Maintenance Dose: 78-234 mg Maximum Monthly Dose: 234 mg Administered 5 weeks after the first injection. The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg). Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.
Side Effects
The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.
Cautions & Contraindications
Warnings & Precautions
Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack).Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring.QT Prolongation: Avoid use with drugs that also increase QT interval and in patients with risk factors for prolonged QT interval.Tardive Dyskinesia: Discontinue drug if clinically appropriate.Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain.Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope.Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Invega Sustenna if clinically significant decline in WBC in the absence of other causative factors.Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration.Potential for Cognitive and Motor Impairment: Use caution when operating machinery.Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.
Contraindications
Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone Palmitate